Table 10.

Clinical studies of lactobacilli showing ability to survive in the gastrointestinal tract

Bacteria	Dose	Site	Ref. (Design)
L. acidophilus 821–3	1×1010 CFU	Gastrointestinal tract	15(open study)
L. acidophilus B. sp	1×108 CFU/g (100 g) 1×107 CFU/g (100 g)	Small intestine	237(open study)
L. casei Shirota	1×108 CFU/mL (100 mL)	Gastrointestinal tract	238(14-day baseline, ingestion and follow-up periods)
L. acidophilus LA02 (DSM 21717) L. rhamnosus LR04 (DSM 16605) L. rhamnosus GG (ATCC 53103) L. rhamnosus LR06 (DSM 21981) B. lactis BS01 (LMG P-21384)	5×109 CFU (of each)	Gastrointestinal tract	239(double-blind, randomised, cross-over study)
L. plantarum LP01 (LMG P-21021) B. breve BR03 (DSM 16604)	1×109 CFU (of each)	Gastrointestinal tract	240(double-blind, randomised, cross-over study)
Lakcid® L (L. rhamnosus 573/1, 573 L/2 and 573L3)	1.2×1010 CFU	Gastrointestinal tract	241(prospective, double-blinded, placebo-controlled randomised study)